ADC Therapeutics (ADCT) Asset Writedowns and Impairment (2023 - 2026)

ADC Therapeutics has disclosed Asset Writedowns and Impairment across 4 years of filings, most recently posting $1.5 million for Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at $1.5 million, up 18.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (up 24.55% YoY), and the FY2025 annual result was $2.3 million, up 50.46% from the prior year.
• Asset Writedowns and Impairment came in at $1.5 million for Q1 2026 at ADC Therapeutics, up from $411000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $1.5 million in Q1 2026 to a low of $53000.0 in Q1 2023.
• The 4-year median for Asset Writedowns and Impairment is $482000.0 (2024), against an average of $625727.3.
• Peak annual rise in Asset Writedowns and Impairment reached 1311.32% in 2024, while the deepest fall reached 60.39% in 2024.
• ADC Therapeutics' Asset Writedowns and Impairment stood at $828000.0 in 2023, then slumped by 41.79% to $482000.0 in 2024, then declined by 14.73% to $411000.0 in 2025, then jumped by 258.39% to $1.5 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $1.5 million (Q1 2026), $411000.0 (Q4 2025), and $237000.0 (Q3 2025), per Business Quant data.